Skip to content
value.today

Dicerna Pharmaceuticals Inc

Total raised
$94 M
3 rounds on record
Latest round
$60 M
Jul 2013
First round on record
Jun 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Dicerna Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2013$60 MNo. 3$50 to $250 million

Dicerna Pharmaceuticals Inc: Raise no. 3, Jul 2013

Investors in this round

13 investors had bought by the notice of Aug 15, 2013: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Dicerna Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $63 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Fambrough · Executive Officer, Director
  • Brian K. Halak · Director
  • David K. Madden · Director
  • Dennis H. Langer · Director
  • Jonathan MacQuitty · Director
  • Peter K. Kolchinsky · Director
  • Stephen K. Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$63,000,000 is the maximum total and $3,000,063 the maximum remaining authorized for sale under the current Certificate of Incorporation.”

Signed by Douglas Fambrough, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 15, 2013. Read the notice at the SEC.

equitySEC
Aug 2010$29 MNo. 2$10 to $50 million

Dicerna Pharmaceuticals Inc: Raise no. 2, Aug 2010

Investors in this round

10 investors had bought by the notice of Oct 28, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Dicerna Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$29 M of $29 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David H. Madden · Executive Officer, Director
  • Douglas Fambrough · Executive Officer, Director
  • Dennis H. Langer · Director
  • James C. Jenson · Director
  • Jonathan H. MacQuitty · Director
  • Stephen Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Fambrough, Ph.D, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Oct 28, 2010. Read the notice at the SEC.

equitySEC
Jun 2010$5 MNo. 1$2 to $10 million

Dicerna Pharmaceuticals Inc: Raise no. 1, Jun 2010

Investors in this round

4 investors had bought by the notice of Jun 28, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Dicerna Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Sale of Notes and Warrants
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C. Madden · Executive Officer, Director
  • Douglas Fambrough · Executive Officer, Director
  • Dennis C. Langer · Director
  • James C. Jenson · Director
  • Jonathan C. MacQuitty · Director
  • Stephen Hoffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Douglas Fambrough, President & CEO. Source: SEC Form D, newest notice filed Jun 28, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dicerna Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Aug 2013).

    SEC Form D · Aug 2013

  • The industry group it chose in its notices: Other.

    SEC Form D · Aug 2013

That is all the official record says: Dicerna Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

16 named in official filings. Open an investor to see everything it has backed.

Investors in Dicerna Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Bain Capital Life Sciences Fund, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bain Capital Life Sciences Investors, LLCFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bain Capital Life Sciences Partners, LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2017)SEC Form 3
BCIP Life Sciences Associates, LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Private Design Fund II, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Private Design International II, Ltd.Companynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations International Master Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Domain Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
DP VIII Associates, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Skyline Venture Management V, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Skyline Venture Partners V LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dicerna Pharmaceuticals Inc
NameRoleNamed in
Douglas FambroughExecutive officerAug 2013
David H. MaddenExecutive officerOct 2010
David C. MaddenExecutive officerJun 2010
Brian K. HalakDirectorAug 2013
David K. MaddenDirectorAug 2013
Dennis H. LangerDirectorAug 2013
Douglas FambroughDirectorAug 2013
Jonathan MacQuittyDirectorAug 2013
Peter K. KolchinskyDirectorAug 2013
Stephen K. HoffmanDirectorAug 2013
David H. MaddenDirectorOct 2010
James C. JensonDirectorOct 2010
Jonathan H. MacQuittyDirectorOct 2010
Stephen HoffmanDirectorOct 2010
David C. MaddenDirectorJun 2010
Dennis C. LangerDirectorJun 2010
Jonathan C. MacQuittyDirectorJun 2010

About

Company in Cambridge, United States.